Shares of Eli Lilly LLY decreased 1.3% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share decreased 1.06% over the past year to $1.87, which missed the estimate of $1.92.
Revenue of $6,740,000,000 higher by 22.57% year over year, which beat the estimate of $6,650,000,000.
Outlook
The upcoming fiscal year's EPS expected to be between $7.80 and $8.00.
The upcoming fiscal year's revenue expected to be between $26,800,000,000 and $27,400,000,000.
Conference Call Details
Date: Aug 03, 2021
Time: 09:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/fy9ujkgu
Recent Stock Performance
Company's 52-week high was at $248.40
52-week low: $129.21
Price action over last quarter: Up 34.87%
Company Profile
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, oncology, and immunology. Lilly's key products include Alimta and Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.